DIN 02538652 — XCOPRI 12.5 MG
XCOPRI is a tablet of Cenobamate marketed by KNIGHT THERAPEUTICS INC.. The full Cenobamate monograph covers indications, dosing, interactions and counselling for every strength and manufacturer.
- DIN
- 02538652
- Brand name
- XCOPRI
- Active ingredient
- Cenobamate
- Strength
- 12.5 MG
- Dosage form
- TABLET
- Route
- ORAL
- Manufacturer
- KNIGHT THERAPEUTICS INC.
- Health Canada status
- MARKETED
- Drug class
- Antiepileptic agent (sodium channel inactivator / GABA-A modulator)
Product data from the Health Canada Drug Product Database, synced . Verify the live status at Health Canada.
Other Cenobamate products
| DIN | Brand | Strength | Form | Manufacturer | Status |
|---|---|---|---|---|---|
| 02538733 | XCOPRI | 100 MG | TABLET | KNIGHT THERAPEUTICS INC. | MARKETED |
| 02538784 | XCOPRI | 100 MG; 50 MG | KIT; TABLET | KNIGHT THERAPEUTICS INC. | MARKETED |
| 02538741 | XCOPRI | 150 MG | TABLET | KNIGHT THERAPEUTICS INC. | MARKETED |
| 02538768 | XCOPRI | 200 MG | TABLET | KNIGHT THERAPEUTICS INC. | MARKETED |
| 02538660 | XCOPRI | 25 MG | TABLET | KNIGHT THERAPEUTICS INC. | MARKETED |
| 02538776 | XCOPRI | 25 MG; 12.5 MG | KIT; TABLET | KNIGHT THERAPEUTICS INC. | MARKETED |
| 02538725 | XCOPRI | 50 MG | TABLET | KNIGHT THERAPEUTICS INC. | MARKETED |